Objectives Ovarian cancer is one of the highest incidence and mortality gynecological tumors. Most of them will relapse within 24 months. The purpose of this study was to compare the efficacy and safety of doxorubicin liposomes or paclitaxel combined with platinum chemotherapy in the treatment of some platinum-sensitive, recurrent ovarian cancer patients.

Methods Ovarian cancer patients who is recurrence in 6–12 months from the last chemotherapy were selected and randomly assigned in a 1:1 ratio to receive paclitaxel or doxorubicin liposome and platinum-based combinations. he primary endpoint is progression-free survival (PFS).

Results A total of 216 ovarian cancer patients were enrolled, 106 of whom received paclitaxel platinum therapy , 110 patients received doxorubicin platinum therapy. Patients in the platinum-based paclitaxel treatment group had a longer PFS (18.0 vs. 14.0 months, hazard ratio, 0.71, 95% confidence interval [CI], 0.44 to 1.45, P>0.05) compared with those in the doxorubicin-platinum group. The disease control rates of the two groups were 88.6% in the paclitaxel group and 86.36% in the doxorubicin group. In the study, the most adverse reactions of grade 3 or 4 in the doxorubicin platinum treatment group were leukopenia (6.4%) and thrombocytopenia (10.9%). The paclitaxel platinum treatment group were leukopenia (8.5%) and thrombocytopenia (3.8%).

Conclusions In the treatment of some platinum-sensitive, recurrent ovarian cancer patients, paclitaxel platinum-based therapy and doxorubicin-platinum therapy have no significant difference in efficacy, and there is no significant difference in adverse reactions. Therefore, in the treatment of platinum-sensitive, recurrent ovarian cancer patients, both options can be used as options. (ClinicalTrials.gov number, NCT04337632)